Denali Therapeutics Inc.
Denali Therapeutics Inc. (NASDAQ: DNLI) is a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, particularly those affecting the central nervous system. The company's core innovation is its proprietary TransportVehicle (TV) platform technology, which enables… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Denali Therapeutics Inc. does
In the company’s own words
Denali Therapeutics Inc. (NASDAQ: DNLI) is a biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, particularly those affecting the central nervous system. The company's core innovation is its proprietary TransportVehicle (TV) platform technology, which enables the delivery of large molecule biotherapeutics across the blood-brain barrier through receptor-mediated transcytosis. This modular platform can transport enzymes, oligonucleotides, antibodies, and other proteins to the brain and throughout the body following systemic administration.
The company's therapeutic portfolio spans three primary franchise areas. The Enzyme TransportVehicle (ETV) franchise targets lysosomal storage disorders and represents the company's nearest commercial opportunity, with tividenofusp alfa for mucopolysaccharidosis II (Hunter syndrome) under FDA review with a PDUFA target action date of April 5, 2026, and DNL126 for mucopolysaccharidosis IIIA (Sanfilippo syndrome type A) in Phase 1/2 development. The Oligonucleotide TransportVehicle (OTV) and Antibody TransportVehicle (ATV) franchises address neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. Additional programs target frontotemporal dementia, Pompe disease, and Gaucher disease.
Denali operates a hybrid manufacturing strategy utilizing both internal capabilities and external contract manufacturers. In March 2025, the company opened a clinical biomanufacturing facility in Salt Lake City, Utah. The company maintains active collaborations with major pharmaceutical partners including Biogen for LRRK2 inhibitor development and Takeda for granulin replacement therapy development.
The company's strategic framework, termed D3X3, targets delivery of two commercial brands, achievement of five clinical proof-of-concept readouts, and advancement of four to six additional TV-enabled programs into clinical development over a three-year period. Denali's business model emphasizes platform validation transitioning to commercial delivery and scalable growth, with revenue from rare disease launches intended to fund development of programs in larger indication markets.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1714899
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Denali Therapeutics Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Denali Therapeutics Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Denali Therapeutics Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Denali Therapeutics Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Denali Therapeutics Inc.'s last four quarterly filings that the numbers alone won't show?”